newsfilter
← Latest News
GlobeNewswire·

Larimar Therapeutics Reports Third Quarter 2025 Financial Results

In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriersConsistent directional improvement across mFARS,